🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementJoint pain improvement vs new joint pain — looking for input

Joint pain improvement vs new joint pain — looking for input

Dr.PeteFamMed Mon, Oct 27, 2025 at 2:56 PM 16 replies 1,432 viewsPage 1 of 4
This thread is more than 7 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Oct 27, 2025 at 2:56 PM#1

The nausea I get is not really nausea, it is an aversion. Food I want in the abstract becomes repellent in front of me, which no side-effect list describes.

What I actually want to know is whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out.

Happy to be told the question itself is wrong.

15 10hyun_seoul, jim_asheville, matt_MKE and 12 others
Reply Quote Save Share Report
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Oct 27, 2025 at 3:09 PM#2

This one has a reasonably settled answer, so here it is. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

14 9tyler_CSCS, VanRx_Mike, steve_okc and 11 others
Reply Quote Save Share Report
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
Oct 27, 2025 at 3:22 PM#3
Dr.GutHealth said:
Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

13 8RetaRick_CA, JenPlateau, SallyK_inj and 10 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
LeilaHI
Member
167
789
Jan 2025
Honolulu, HI
Oct 27, 2025 at 3:35 PM#4
Dr.PeteFamMed said:
The nausea I get is not really nausea, it is an aversion.

Same position here, arrived at the long way round. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

Last edited: Oct 27, 2025 at 8:35 PM
12 7LondonLisa, mike_nyc, VendorMark and 9 others
Reply Quote Save Share Report
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Oct 27, 2025 at 4:43 PM#5

Adding the clinical framing, because it changes how the question reads. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

Last edited: Oct 27, 2025 at 5:43 PM
11 6Dr.NateNeph, PharmD_Rodriguez, julia.endo and 8 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register